Business & Finance

Cell therapy company provides research and financial update

Published in Blood Weekly, May 19th, 2005

PharmaFrontiers Corp. (PFTR) provided an update on its research programs and future plans. In addition, the company reported financial results for the 12 months ended December 31, 2004.

"We began our journey as a public company during May 2004 with the completion of a reverse merger into a public shell, and strengthened our pipeline of potential therapies for the treatment of several debilitating diseases," said David B. McWilliams, president and chief executive officer of PharmaFrontiers.

In November 2004, the company acquired Opexa Pharmaceuticals, which held the rights to Tovaxin, a novel autologous therapeutic T cell treatment for multiple...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-05-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry